Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)

NCT04817540 is registered in ClinicalTrials.gov with Gangnam Severance Hospital as lead sponsor.

NCT NCT04817540
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04817540 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Anti-HER2 Treatment in HER2-enriched Early Breast Cancer Identified by PAM50 (HER2E-PAM, PAMILIA Study)
Lead sponsor
Gangnam Severance Hospital
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2021
Completion date
March 30, 2027
Enrollment
59 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2 enriched subtype breast cancer, herzuma, pam50 study